Hacken ET, Wu CJ. Understanding CLL biology through mouse models of human genetics. Blood. 2021;138(25):2621-2631. doi:10.1182/blood.2021011993.

Yates K, Bi K, Haining N, Cantor H, Kim H-J. Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells. Proc Natl Acad Sci U S A. 2018;115(9):2162-2167. doi:10.1073/pnas.1720447115.

Meder L, König K, Dietlein F, et al. LIN28B enhanced tumorigenesis in an autochthonous KRAS-driven lung carcinoma mouse model. Oncogene. 2018;37(20):2746-2756. doi:10.1038/s41388-018-0158-7.

Zwang Y, Jonas O, Chen C, et al. Synergistic interactions with PI3K inhibition that induce apoptosis. Elife. 2017;6. doi:10.7554/eLife.24523.

Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156-1160. doi:10.1126/science.aah5043.

Dudani JS, Ibrahim M, Kirkpatrick J, Warren AD, Bhatia SN. Classification of prostate cancer using a protease activity nanosensor library. Proc Natl Acad Sci U S A. 2018;115(36):8954-8959. doi:10.1073/pnas.1805337115.

Sade-Feldman M, Jiao YJ, Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. doi:10.1038/s41467-017-01062-w.

Lee JC, Vivanco I, Beroukhim R, et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006;3(12):e485. doi:10.1371/journal.pmed.0030485.

Greulich H, Chen T-H, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2005;2(11):e313. doi:10.1371/journal.pmed.0020313.

Zhou AY, Shen RR, Kim E, et al. IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Rep. 2013;3(3):724-33. doi:10.1016/j.celrep.2013.01.031.